Naoki Tani

450 total citations
38 papers, 297 citations indexed

About

Naoki Tani is a scholar working on Infectious Diseases, Epidemiology and Molecular Biology. According to data from OpenAlex, Naoki Tani has authored 38 papers receiving a total of 297 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Infectious Diseases, 11 papers in Epidemiology and 7 papers in Molecular Biology. Recurrent topics in Naoki Tani's work include SARS-CoV-2 and COVID-19 Research (16 papers), Influenza Virus Research Studies (10 papers) and Respiratory viral infections research (9 papers). Naoki Tani is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (16 papers), Influenza Virus Research Studies (10 papers) and Respiratory viral infections research (9 papers). Naoki Tani collaborates with scholars based in Japan and Spain. Naoki Tani's co-authors include Masaru Ohtsuru, Tadao Hata, Yong Chong, Hideyuki Ikematsu, Nobuyuki Shimono, HATSUO AOKI, Chung‐gi Shin, JUNJI HOSODA, Hiroshi Imanaka and Yasuchika Yonezawa and has published in prestigious journals such as PLoS ONE, Vaccine and Antiviral Research.

In The Last Decade

Naoki Tani

36 papers receiving 285 citations

Peers

Countries citing papers authored by Naoki Tani

Since Specialization

Citations

This map shows the geographic impact of Naoki Tani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naoki Tani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naoki Tani more than expected).

Fields of papers citing papers by Naoki Tani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naoki Tani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naoki Tani. The network helps show where Naoki Tani may publish in the future.

Co-authorship network of co-authors of Naoki Tani

This figure shows the co-authorship network connecting the top 25 collaborators of Naoki Tani. A scholar is included among the top collaborators of Naoki Tani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Naoki Tani. Naoki Tani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Impact of the Number of Vaccinations on the Duration of Fever and Symptoms in Adult Patients with Mild COVID-19 during the Period of Spread of the Omicron Variant of SARS-CoV-2 in Japan 2024 ·Kansenshogaku zasshi ·(unknown), (unknown), Masashi Mizuguchi, (unknown), Naoki Tani, Yong Chong, Hideyuki Ikematsu	1
2	In vitro neuraminidase inhibitory concentrations (IC50) of four neuraminidase inhibitors in the Japanese 2023–24 season: Comparison with the 2010–11 to 2022–23 seasons 2024 ·Journal of Infection and Chemotherapy ·(unknown), Naoki Kawai, (unknown), Tomonori Sato, Naoki Tani, Yong Chong, Hideyuki Ikematsu	1
3	Virological and clinical outcomes in outpatients treated with baloxavir or neuraminidase inhibitors for A(H3N2) influenza: A multicenter study of the 2022–2023 season 2024 ·Antiviral Research ·(unknown), Naoki Kawai, (unknown), (unknown), (unknown), Naoki Tani, Yong Chong, Hideyuki Ikematsu	4
4	Reduction of adverse reactions and correlation between post-vaccination fever and specific antibody response across successive SARS-CoV-2 mRNA vaccinations 2024 ·Vaccine X ·Naoki Tani, Hideyuki Ikematsu, (unknown), (unknown), (unknown), Yasuo Kurata, (unknown), Takahiko Horiuchi, Koichi Akashi, Nobuyuki Shimono, Yong Chong	2
5	Distinct features of SARS-CoV-2 humoral immunity against Omicron breakthrough infection 2023 ·Vaccine ·(unknown), Yong Chong, Naoki Tani, (unknown), (unknown), (unknown), Masahiro Taniguchi, Takahiro Kusakabe, Nobuyuki Shimono, Koichi Akashi, Hideyuki Ikematsu	1
6	Correlation between specific antibody response to wild-type BNT162b2 booster and the risk of breakthrough infection with omicron variants: Impact of household exposure in hospital healthcare workers 2023 ·Vaccine ·Naoki Tani, Hideyuki Ikematsu, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Takahiko Horiuchi, Hiroyuki Kuwano, Koichi Akashi, Nobuyuki Shimono, Yong Chong	1
7	Achievement of sufficient antibody response after a fourth dose of wild‐type SARS‐CoV‐2 mRNA vaccine in nursing home residents 2023 ·Immunity Inflammation and Disease ·Yong Chong, (unknown), (unknown), Naoki Tani, Akiko Yonekawa, Hideyuki Ikematsu, Nobuyuki Shimono, Yosuke Tanaka, Koichi Akashi	2
8	Correlation of Postvaccination Fever With Specific Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 BNT162b2 Booster and No Significant Influence of Antipyretic Medication 2022 ·Open Forum Infectious Diseases ·Naoki Tani, Hideyuki Ikematsu, (unknown), (unknown), (unknown), (unknown), Yasuo Kurata, (unknown), (unknown), (unknown), (unknown), Hiroyuki Kuwano, Koichi Akashi, Nobuyuki Shimono, Yong Chong	11
9	Pronounced antibody elevation after SARS‐CoV‐2 BNT162b2 mRNA booster vaccination in nursing home residents 2022 ·Influenza and Other Respiratory Viruses ·Yong Chong, (unknown), Naoki Tani, Akiko Yonekawa, Hideyuki Ikematsu, Nobuyuki Shimono, Yosuke Tanaka, Koichi Akashi	10
10	Post-vaccination antibody evaluation for nosocomial SARS-CoV-2 delta variant breakthrough infection 2022 ·PLoS ONE ·(unknown), Naoki Tani, Hideyuki Ikematsu, (unknown), (unknown), (unknown), (unknown), Hiroyuki Kuwano, Koichi Akashi, Nobuyuki Shimono, Yong Chong	1
11	No significant influence of pre-vaccination antipyretic use on specific antibody response to a BNT162b2 vaccine booster against COVID-19 2022 ·Vaccine X ·Naoki Tani, Hideyuki Ikematsu, (unknown), (unknown), (unknown), Yasuo Kurata, (unknown), (unknown), (unknown), (unknown), Hiroyuki Kuwano, Koichi Akashi, Nobuyuki Shimono, Yong Chong	4
12	Monitoring of Adverse Events Associated with COVID-19 Vaccine (Tozinameran) -Influence of Sex, Age, and Number of Doses on the Frequencies of Adverse Reactions- 2022 ·Kansenshogaku zasshi ·Yasuo Kurata, (unknown), (unknown), (unknown), Naoki Tani, (unknown), (unknown), (unknown), (unknown), Hiroyuki Kuwano	0
13	Susceptibility of epidemic viruses to neuraminidase inhibitors and treatment-emergent resistance in the Japanese 2019-20 influenza season 2021 ·Journal of Infection ·Naoki Tani, Naoki Kawai, Yong Chong, (unknown), Norio Iwaki, Seizaburo Kashiwagi, Hideyuki Ikematsu	7
14	Relationship Between Long-Term Objectively Measured Physical Activity and Glycemic Control in Type 2 Diabetes Mellitus Patients: A Prospective Cohort Study 2021 ·Diabetes Metabolic Syndrome and Obesity ·Hiroaki Masuda, Daisuke Ishiyama, Minoru Yamada, (unknown), Yosuke Kimura, Yuhei Otobe, Naoki Tani, Mizue Suzuki, Hideki Nakajima	4
15	Genetic testing and serological screening for SARS-CoV-2 infection in a COVID-19 outbreak in a nursing facility in Japan 2021 ·BMC Infectious Diseases ·Yong Chong, Naoki Tani, Hideyuki Ikematsu, (unknown), Hitoshi Nakashima, Nobuyuki Shimono, Koichi Akashi, Yosuke Tanaka	5
16	Virological and clinical outcomes in outpatients treated with baloxavir or oseltamivir: A Japanese multicenter study in the 2019–2020 influenza season 2021 ·Antiviral Research ·Yong Chong, Naoki Kawai, Naoki Tani, (unknown), (unknown), (unknown), Hideyuki Ikematsu	9
17	Clinical significance of SARS‐CoV‐2‐specific IgG detection with a rapid antibody kit for COVID‐19 patients 2020 ·Influenza and Other Respiratory Viruses ·Yong Chong, Hideyuki Ikematsu, Naoki Tani, (unknown), (unknown), (unknown), Akiko Yonekawa, (unknown), (unknown), Yoshihiro Eriguchi, Noriko Miyake, Shinji Shimoda, Yoji Nagasaki, Nobuyuki Shimono, Koichi Akashi	5
18	In vitro neuraminidase inhibitory concentration (IC50) of four neuraminidase inhibitors in the Japanese 2018–19 season: Comparison with the 2010–11 to 2017–18 seasons 2020 ·Journal of Infection and Chemotherapy ·Hideyuki Ikematsu, Naoki Kawai, Naoki Tani, Yong Chong, (unknown), Norio Iwaki, Seizaburo Kashiwagi	11
19	The Effects of Font Type on Reading Accuracy and Fluency in Japanese Children with Developmental Dyslexia 2019 ·(unknown), Akira Uno, Naoki Tani, (unknown), Toshimasa Yamanaka	2
20	Duration of fever and PA/I38X-substituted virus emergence in patients treated with baloxavir in the 2018–2019 influenza season 2019 ·Journal of Infection and Chemotherapy ·Hideyuki Ikematsu, Naoki Kawai, Naoki Tani, Yong Chong, Norio Iwaki, (unknown), (unknown), (unknown), Tetsunari Maeda, (unknown)	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact